Loading...
XSHE000153
Market cap382mUSD
Jan 08, Last price  
6.03CNY
1D
-0.33%
1Q
2.90%
Jan 2017
-53.22%
Name

Anhui Fengyuan Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:000153 chart
P/E
17.59
P/S
0.66
EPS
0.34
Div Yield, %
2.29%
Shrs. gr., 5y
7.95%
Rev. gr., 5y
7.25%
Revenues
4.28b
+6.78%
280,542,183441,214,907521,294,703703,778,687873,807,853955,695,4751,074,181,7771,516,487,7431,657,764,5121,529,898,1151,698,945,4201,554,294,5382,033,683,3952,578,105,4363,013,395,3643,238,064,4373,321,182,3653,501,668,7424,004,020,3814,275,436,713
Net income
159m
+3.15%
9,591,2039,025,12222,005,0015,634,33614,183,56822,986,18541,625,5199,913,12319,018,89327,346,62440,990,92032,389,55745,836,28865,348,14160,926,37780,921,045103,720,155122,983,675154,426,589159,285,567
CFO
255m
-42.10%
034,877,10136,268,69155,259,46749,822,55932,405,22955,037,40755,063,47145,650,433010,510,49745,498,59978,211,86652,395,110233,592,50466,213,294292,753,328237,881,716439,990,375254,751,792
Dividend
Jun 07, 20240.21 CNY/sh
Earnings
May 22, 2025

Profile

Anhui Fengyuan Pharmaceutical Co., Ltd. researches and develops, produces, and sells biological pharmacy, chemical pharmacy, and traditional Chinese medicines primarily in China. It offers antipyretic-analgesic, cardiovascular, antibiotic, nervous system, anti-tumor, antiulcer, and hormone drugs, as well as nutraceuticals. The company also provides general medicines for vitamin and mineral deficiency; medicines for resisting parasitic diseases and microorganisms; coenzymes; and antiviral and uterine contractive medicines. In addition, it offers sedative-hypnotic drugs; drugs for curing mesenteric stress syndrome; drugs for lowering blood pressure; and drugs for curing benign prostatic hyperplasia. The company also exports its products to Europe, North America, Africa, Southeast Asia, and Central Asia. Anhui Fengyuan Pharmaceutical Co., Ltd. was founded in 1997 and is based in Hefei, China.
URL
http://www.bbcayy.com/
IPO date
Sep 20, 2000
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
4,275,437
6.78%
4,004,020
14.35%
Cost of revenue
3,869,562
3,653,961
Unusual Expense (Income)
NOPBT
405,874
350,059
NOPBT Margin
9.49%
8.74%
Operating Taxes
57,596
51,352
Tax Rate
14.19%
14.67%
NOPAT
348,279
298,708
Net income
159,286
3.15%
154,427
25.57%
Dividends
(64,175)
(31,214)
Dividend yield
1.47%
Proceeds from repurchase of equity
(348)
BB yield
0.01%
Debt
Debt current
473,093
598,399
Long-term debt
215,179
210,272
Deferred revenue
238,046
151,924
Other long-term liabilities
Net debt
5,921
(111,232)
Cash flow
Cash from operating activities
254,752
439,990
CAPEX
(152,116)
Cash from investing activities
(143,657)
Cash from financing activities
(165,202)
FCF
203,727
84,704
Balance
Cash
319,905
353,138
Long term investments
362,445
566,765
Excess cash
468,579
719,702
Stockholders' equity
1,250,178
1,717,928
Invested Capital
2,356,350
1,906,870
ROIC
16.34%
16.57%
ROCE
14.24%
13.19%
EV
Common stock shares outstanding
464,970
317,163
Price
9.37
 
Market cap
4,356,772
 
EV
4,392,110
EBITDA
532,193
471,760
EV/EBITDA
8.25
Interest
33,894
32,865
Interest/NOPBT
8.35%
9.39%